Accéder au contenu
Merck

S2064

SC-560

≥98% (HPLC)

Synonyme(s) :

5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethyl pyrazole

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement


A propos de cet article

Formule empirique (notation de Hill) :
C17H12ON2ClF3
Numéro CAS:
Poids moléculaire :
352.74
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
51111800
MDL number:
Assay:
≥98% (HPLC)
Quality level:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

InChI key

PQUGCKBLVKJMNT-UHFFFAOYSA-N

SMILES string

COc1ccc(cc1)-n2nc(cc2-c3ccc(Cl)cc3)C(F)(F)F

InChI

1S/C17H12ClF3N2O/c1-24-14-8-6-13(7-9-14)23-15(10-16(22-23)17(19,20)21)11-2-4-12(18)5-3-11/h2-10H,1H3

assay

≥98% (HPLC)

solubility

DMSO: >20 mg/mL

storage temp.

2-8°C

Quality Level

Gene Information

Catégories apparentées

Application

SC-560 has been used as a cyclooxygenase-1 (COX-1) inhibitor to study its effects on prostaglandin E-2 (PGE2) signaling in ciliogenesis in zebrafish embryos. It has also been used as a selective inhibitor of COX-1 to study its role in PM10-induced endothelial dysfunction.

Biochem/physiol Actions

SC-560 (5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-(trifluoromethyl)-1H-pyrazole) is a non-steroidal anti-inflammatory drug (NSAID). It is a lipophilic, diaryl heterocyclic compound. SC-560 acts as an effective antiviral agent against hepatitis C virus (HCV). It also has a potential to hinder prostaglandin E2 synthesis in neurons at nanomolar concentrations.
SC-560 belongs to the diaryl heterocycle class of cyclooxygenase (COX) inhibitors. It exhibits anti-tumor and anti-proliferative activities.
Selective cyclooxygenase-1 (COX-1) inhibitor, exhibiting 700-fold selectivity for COX-1 over COX-2.

Classe de stockage

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Dan Wang et al.
Antioxidants (Basel, Switzerland), 11(5) (2022-05-29)
Nuclear factor erythroid factor E2-related factor 2 (Nrf2) transcribes antioxidant genes that reduce the blood pressure (BP), yet its activation with tert-butylhydroquinone (tBHQ) in mice infused with angiotensin II (Ang II) increased mean arterial pressure (MAP) over the first 4
Edwin S L Chan et al.
Arthritis research & therapy, 9(1), R4-R4 (2007-01-25)
Both selective cyclooxygenase (COX)-2 inhibitors and non-steroidal anti-inflammatory drugs (NSAIDs) have been beneficial pharmacological agents for many patients suffering from arthritis pain and inflammation. However, selective COX-2 inhibitors and traditional NSAIDs are both associated with heightened risk of myocardial infarction.
G O'Callaghan et al.
British journal of cancer, 99(3), 502-512 (2008-07-24)
Fas ligand (FasL/CD95L) is a member of the tumour necrosis factor superfamily that triggers apoptosis following crosslinking of the Fas receptor. Despite studies strongly implicating tumour-expressed FasL as a major inhibitor of the anti-tumour immune response, little is known about
Alessandra Pannunzio et al.
Pharmaceuticals (Basel, Switzerland), 11(4) (2018-10-14)
Prostaglandins and thromboxane are lipid signaling molecules deriving from arachidonic acid by the action of the cyclooxygenase isoenzymes COX-1 and COX-2. The role of cyclooxygenases (particularly COX-2) and prostaglandins (particularly PGE₂) in cancer-related inflammation has been extensively investigated. In contrast
Cyclooxygenase-1 (COX-1) and COX-1 inhibitors in cancer: a review of oncology and medicinal chemistry literature
Pannunzio A and Coluccia M
Pharmaceuticals (Basel, Switzerland), 11(4), 101-101 (2018)

Contenu apparenté

Instructions

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique